Patients with type 2 diabetes mellitus (T2DM) that have elevated levels of blood glucose and glycated hemoglobin are at higher risk of macro- and microvascular complications.
TORONTO and PHILADELPHIA, Feb. 8, 2023 /PRNewswire/ -- JMIR Publications published "Clinical Utility of a Digital Therapeutic Intervention in Indian Patients With Type 2 Diabetes Mellitus: 12-Week Prospective Single-Arm Intervention Study" in their journal JMIR Diabetes, which reported that patients with type 2 diabetes mellitus (T2DM) that have elevated levels of blood glucose and glycated hemoglobin are at higher risk of macro- and microvascular complications.
The aim of this study was to examine the clinical utility of a digital therapeutic intervention (DTI) as an add-on therapy to achieve glycemic control in patients with T2DM. This was a 12-week prospective, single-arm digital intervention study in patients with T2DM receiving regular antidiabetic treatment.
The outcome measures of the study were mean changes in HbA1c, fasting blood glucose (FBG), postprandial blood glucose (PPBG), BMI, and Homeostatic Model Assessment for Insulin Resistance index at the end of 12 weeks. At the end of 12 weeks, the mean change in HbA1c, FBG, PPBG, and BMI for the overall study population was -0.84%
Dr Suhas Patil from Terrals Technologies Private Ltd said, "Type 2 diabetes mellitus (T2DM) is a metabolic endocrine disorder that is characterized by continually elevated blood glucose levels."
As a chronic progressive disease, the medical management of T2DM often necessitates the intensification of medications during the course of treatment. However, there is also compelling evidence to support the role of therapeutic lifestyle changes such as weight loss, dietary restrictions, exercise, adequate sleep, and health coaching in the effective management of diabetes without requiring the intensification of the medications.
In recent years, digital technologies have attracted increasing attention for enabling lifestyle modifications for patients and helping them achieve the goal of diabetes self-management to reduce the disease burden. As a mostly remote intervention form, DTIs may not be as impactful as in-person counseling and follow-ups, but they have the advantage of ease of communication, anytime-anywhere accessibility, and availability of information.
Several studies have demonstrated the role of digital technology, such as digital therapeutic platforms, telehomecare systems, digitally enhanced diabetes self-management, education and support programs, as well as smartphone-based integrated online real-time diabetes care systems, for the effective management of T2DM without requiring escalation of existing medication.
The research team concluded in their JMIR Publications Research Output, "The use of a DTI as an adjunct therapy to conventional medications significantly reduced HbA1c, FBG, and PPBG levels in patients with T2DM. This in turn may reduce the risk of cardiovascular complications as well as all-cause mortality associated with T2DM."
DOI - https://doi.org/10.2196/41401
Full-text - https://diabetes.jmir.org/2022/4/e41401/
Free Altmetric Report - https://jmir.altmetric.com/details/137903641
Keywords - HbA1c, type 2 diabetes, digital therapeutics, fasting blood glucose, postprandial blood glucose, mHealth, digital health intervention, glycemic control, mobile health
JMIR Publications is a leading, born-digital, open access publisher of 30+ academic journals and other innovative scientific communication products that focus on the intersection of health and technology. Its flagship journal, the Journal of Medical Internet Research, is the leading digital health journal globally in content breadth and visibility, and it is the largest journal in the medical informatics field.
To learn more about JMIR Publications, please visit https://www.JMIRPublications.com or connect with us via:
YouTube - https://www.youtube.com/c/JMIRPublications
Facebook - https://www.facebook.com/JMedInternetRes
Twitter - https://twitter.com/jmirpub
LinkedIn - https://www.linkedin.com/company/jmir-publications
Instagram - https://www.instagram.com/jmirpub/
Head Office - 130 Queens Quay East, Unit 1100 Toronto, ON, M5A 0P6 Canada
Media Contact - [email protected]
The content of this communication is licensed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, published by JMIR Publications, is properly cited.
JMIR Publications is a registered trademark of JMIR Publications.
Provided by Newswise, online resource for knowledge-based news at www.newswise.com
Media Contacts: Ryan James Jessup JD/MPA Publication Communications Specialist Communications & Knowledge Translation Department [email protected] Mobile: (202) 638 9720
Advertisement
TORONTO and PHILADELPHIA, Feb. 8, 2023 /PRNewswire/ -- JMIR Publications published "Clinical Utility of a Digital Therapeutic Intervention in Indian Patients With Type 2 Diabetes Mellitus: 12-Week Prospective Single-Arm Intervention Study" in their journal JMIR Diabetes, which reported that patients with type 2 diabetes mellitus (T2DM) that have elevated levels of blood glucose and glycated hemoglobin are at higher risk of macro- and microvascular complications.
Advertisement
The aim of this study was to examine the clinical utility of a digital therapeutic intervention (DTI) as an add-on therapy to achieve glycemic control in patients with T2DM. This was a 12-week prospective, single-arm digital intervention study in patients with T2DM receiving regular antidiabetic treatment.
The outcome measures of the study were mean changes in HbA1c, fasting blood glucose (FBG), postprandial blood glucose (PPBG), BMI, and Homeostatic Model Assessment for Insulin Resistance index at the end of 12 weeks. At the end of 12 weeks, the mean change in HbA1c, FBG, PPBG, and BMI for the overall study population was -0.84%
Dr Suhas Patil from Terrals Technologies Private Ltd said, "Type 2 diabetes mellitus (T2DM) is a metabolic endocrine disorder that is characterized by continually elevated blood glucose levels."
As a chronic progressive disease, the medical management of T2DM often necessitates the intensification of medications during the course of treatment. However, there is also compelling evidence to support the role of therapeutic lifestyle changes such as weight loss, dietary restrictions, exercise, adequate sleep, and health coaching in the effective management of diabetes without requiring the intensification of the medications.
In recent years, digital technologies have attracted increasing attention for enabling lifestyle modifications for patients and helping them achieve the goal of diabetes self-management to reduce the disease burden. As a mostly remote intervention form, DTIs may not be as impactful as in-person counseling and follow-ups, but they have the advantage of ease of communication, anytime-anywhere accessibility, and availability of information.
Several studies have demonstrated the role of digital technology, such as digital therapeutic platforms, telehomecare systems, digitally enhanced diabetes self-management, education and support programs, as well as smartphone-based integrated online real-time diabetes care systems, for the effective management of T2DM without requiring escalation of existing medication.
The research team concluded in their JMIR Publications Research Output, "The use of a DTI as an adjunct therapy to conventional medications significantly reduced HbA1c, FBG, and PPBG levels in patients with T2DM. This in turn may reduce the risk of cardiovascular complications as well as all-cause mortality associated with T2DM."
DOI - https://doi.org/10.2196/41401
Full-text - https://diabetes.jmir.org/2022/4/e41401/
Free Altmetric Report - https://jmir.altmetric.com/details/137903641
Keywords - HbA1c, type 2 diabetes, digital therapeutics, fasting blood glucose, postprandial blood glucose, mHealth, digital health intervention, glycemic control, mobile health
JMIR Publications is a leading, born-digital, open access publisher of 30+ academic journals and other innovative scientific communication products that focus on the intersection of health and technology. Its flagship journal, the Journal of Medical Internet Research, is the leading digital health journal globally in content breadth and visibility, and it is the largest journal in the medical informatics field.
To learn more about JMIR Publications, please visit https://www.JMIRPublications.com or connect with us via:
YouTube - https://www.youtube.com/c/JMIRPublications
Facebook - https://www.facebook.com/JMedInternetRes
Twitter - https://twitter.com/jmirpub
LinkedIn - https://www.linkedin.com/company/jmir-publications
Instagram - https://www.instagram.com/jmirpub/
Head Office - 130 Queens Quay East, Unit 1100 Toronto, ON, M5A 0P6 Canada
Media Contact - [email protected]
The content of this communication is licensed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, published by JMIR Publications, is properly cited.
JMIR Publications is a registered trademark of JMIR Publications.
Provided by Newswise, online resource for knowledge-based news at www.newswise.com
Media Contacts: Ryan James Jessup JD/MPA Publication Communications Specialist Communications & Knowledge Translation Department [email protected] Mobile: (202) 638 9720
View original content:https://www.prnewswire.com/news-releases/jmir-diabetes--clinical-utility-of-digital-therapeutic-intervention-with-type-2-diabetes-301742034.html
SOURCE JMIR Publications
